

**South East London Area Prescribing Committee**

**Withdrawal of formulary recommendation number 008  
(issued March 2014):**

Dymista® (137 micrograms azelastine hydrochloride/ 50 micrograms fluticasone propionate per actuation) nasal spray for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

This formulary recommendation has been withdrawn as following a re-submission Dymista® is accepted for use in South East London in line with the criteria set out in the SEL Allergic Rhinitis treatment pathway.

Please refer to [Recommendation 067](#) and the [treatment pathway](#) for further information.

Please contact [contactus@selondonics.nhs.uk](mailto:contactus@selondonics.nhs.uk) for further information.

**June 2017**